No Data
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its ARTISTRY-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Express News | Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its Artistry-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for Immunotherapy of Cancer
Morgan Stanley Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $13
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)
Express News | Mural Oncology PLC Files for Mixed Shelf Offering of up to $300 Mln- SEC Filing
H.C. Wainwright Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $18